DV
Dividend Vision

BNR Stock — Burning Rock Biotech Ltd

Burning Rock Biotech Ltd (BNR)

Updated October 16, 2026.

BNR is a Stock. Total return is -94.8% over the past 6.3 years, 269.1 points behind SPY at 174.3%.

Burning Rock Biotech Limited develops and commercializes cancer diagnostic tests based on next-generation sequencing technology, operating in China and the United States through central laboratory services, in-hospital testing, and pharmaceutical research partnerships. The company offers a suite of NGS-based tissue and liquid biopsy tests for multiple cancer types, along with data analysis tools and reagent kits, with collaborations spanning major pharmaceutical companies including AstraZeneca, Bayer, and Johnson & Johnson. The company does not currently distribute to shareholders.

BNR performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.8% over the past 6.3 years, 269.1 points behind SPY at 174.3%. Over the past year its total return — price change plus distributions reinvested — is 60.7%. Its deepest 1-year drawdown was 82.9%.

WindowTotal returnCAGR
1M3.0%—
3M34.3%—
6M-42.7%—
YTD-36.0%—
1Y60.7%—
2Y CAGR—109.90%
3Y CAGR—4.50%
5Y CAGR—-38.20%
Since inception (6.3 years)-94.8%-37.20%

BNR key facts

Asset type
Stock
Asset class
Equity
Inception date
06/12/2020
Distribution frequency
None
Last close
$12.90 (as of 2026-10-16)
Market cap
$113,698,768
Average volume
24909.0
Beta
1.294
Payout ratio
0.0%
EPS
$-0.80

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BNR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 82.9%.

Who may consider BNR — and who may not

It is a weaker fit for investors who need monthly cash flow (BNR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BNR

Tagged: Healthcare.

Frequently asked questions

Does BNR pay monthly?

No. BNR does not currently distribute.

When does BNR pay a dividend?

BNR does not currently distribute.

How has BNR performed?

Total return is -94.8% over the past 6.3 years, 269.1 points behind SPY at 174.3%. Over the past year its total return — price change plus distributions reinvested — is 60.7%. Its deepest 1-year drawdown was 82.9%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.